Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.

@article{Wuttke2002IncreasedFO,
  title={Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.},
  author={Henrike Wuttke and T. Rau and Roland Heide and Klaus Bergmann and Michael B{\"o}hm and Joachim Weil and D. W. Croisdale H. Kamp H. Werner and Thomas Eschenhagen},
  journal={Clinical pharmacology and therapeutics},
  year={2002},
  volume={72 4},
  pages={429-37}
}
OBJECTIVE The CYP2D6 genotype is a major determinant of interindividual differences in metoprolol plasma clearance. Cytochrome P450 2D6 (CYP2D6) poor metabolizers exhibit 3- to 10-fold higher plasma concentrations after administration of metoprolol than extensive metabolizers. However, the impact of the CYP2D6 genotype on the occurrence of adverse effects of metoprolol remains controversial. This study addressed whether the incidence of poor metabolizers was higher in patients with metoprolol… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 55 extracted citations

Antidepressants, metoprolol and the risk of bradycardia.

Therapeutic advances in psychopharmacology • 2012
View 4 Excerpts
Highly Influenced

Chronic heart failure: β-blockers and pharmacogenetics

European Journal of Clinical Pharmacology • 2008
View 6 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…